ALLO Allogene Therapeutics, Inc.

2d ago, source: Seeking Alpha

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops ...

Allogene Therapeutics gets grant for patent granted for CD19-specific CARS resistant to rituximab

10d ago, source: Pharmaceutical Technology

Discover the groundbreaking patent by Allogene Therapeutics for CD19-specific CARs resistant to rituximab binding. Learn about the innovative methods and features of these engineered immune cells.

Allogene Therapeutics Announces Q2 Investor Conference Participation

24d ago, source: Nasdaq

JPM Securities Life Sciences Conference Tuesday, May 14, 20246:00am PT/9:00am ET Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the ...

Allogene Therapeutics Inc ALLO

12d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

How Allogene (ALLO) Stock Stands Out in a Strong Industry

25d ago, source: Yahoo Finance

One stock that might be an intriguing choice for investors right now is Allogene Therapeutics, Inc. ALLO. This is because this security in the Medical - Biomedical and Genetics space is seeing ...

Allogene Therapeutics Announces Q2 Investor Conference Participation

25d ago, source: Yahoo Finance

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ...

Allogene Therapeutics Inc (ALLO)

3d ago, source: Investing

Gilead Sciences’ GILD Kite announced positive top-line results from the primary analysis of the global phase III multicenter study, ZUMA-7.ZUMA-7 evaluated a one-time ...

Allogene Therapeutics Inc (ALLO)

25d ago, source: Investing

Allogene Therapeutics (NASDAQ:ALLO), the biotechnology company specializing in allogeneic CAR T therapies, has recently provided an update on its clinical trials and financial ...